ADMA Biologics spent much of 2025 telling Wall Street a story investors wanted to hear: record revenue of $510 million, a 20% year-over-year surge, and its flagship immunoglobulin therapy ASCENIV posting a jaw-dropping 51% growth rate. The stock climbed accordingly. Then, on March 24, 2026, an investigative short-seller named Culper Research published a report with a blunt title — "Channel Stuffing, an Undisclosed Related Party Distributor, and –3% Real Growth in 2025 vs. +20% Reported" — and the story fell apart at the seams.

Culper's central accusation was specific and damaging: that ADMA had induced at least one distributor to absorb excess quantities of ASCENIV by offering rebates and extended payment terms, allowing the company to book revenue it had not actually earned through genuine end-user demand. In the parlance of securities fraud, that is channel stuffing — the oldest trick in the manufacturing playbook, dressed up here in the language of a specialty biopharmaceutical launch. The report went further, alleging that the distributor in question was a related party operating, improbably, from ADMA's own headquarters — a relationship, Culper alleged, that was never disclosed to investors.

The market's immediate verdict was unambiguous. ADMA shares fell $2.26, or 16.6%, on March 24 alone, dropping from a closing price of $13.59 the prior session to $11.33. The selling continued. By the time the dust settled, the stock had shed roughly 29% from pre-report levels, erasing hundreds of millions of dollars in market capitalization from the accounts of ordinary shareholders who had taken the company's quarterly earnings presentations at face value.

ADMA's management did not stay quiet. Within days, the company issued a formal rebuttal calling Culper's allegations "unsubstantiated, misleading and inaccurate," and took a shot at the messenger — pointing out, accurately, that Culper had disclosed a short position in ADMA stock before publishing the report. The company insisted that end-user demand and clinical utilization for ASCENIV were genuine and continuing to grow across key metrics. It characterized the report as a financially motivated hit piece consistent with a pattern of similar attacks Culper had made against other public companies. That is a legitimate point to raise. It is also the standard playbook for every company ever caught in a channel stuffing scandal.

What makes the legal case more than just a short-seller circus is the federal complaint filed on behalf of shareholders, which leans on a framework that courts take seriously. The suit, pending in U.S. federal court, asserts violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and SEC Rule 10b-5 promulgated thereunder — the core anti-fraud statutes of American securities law. The complaint covers a class period running from August 9, 2024 through March 25, 2026, meaning plaintiffs allege the company made materially false or misleading statements to investors across roughly nineteen months of earnings calls, press releases, and public filings. The four core allegations are: that ADMA engaged in an undisclosed related-party transaction; that it employed channel stuffing to inflate the appearance of revenue; that it lacked adequate internal financial controls; and that all public statements about its business, operations, and financial prospects were materially false as a result.

The product at the center of it all is ASCENIV, an intravenous immunoglobulin therapy derived from donated human plasma, FDA-approved for the treatment of primary humoral immunodeficiency disease in adults and adolescents. ADMA manufactures ASCENIV at its facility in Boca Raton, Florida, making it one of a small number of domestic end-to-end plasma biologics producers. The drug has genuine clinical utility, and that matters — because channel stuffing does not require a product to be fraudulent. It only requires a company to move inventory to the distribution channel faster than it moves out the other end to actual patients, then book the distribution shipment as revenue. If Culper's analysis is correct, ADMA's vaunted ASCENIV growth numbers were partly a function of inventory accumulating in a distributor's warehouse, not drugs reaching immunocompromised patients.

The August 10, 2026 deadline approaching in federal court is specifically the lead plaintiff deadline under the Private Securities Litigation Reform Act of 1995 — the point by which any investor who suffered losses during the class period must apply to the court to serve as the named lead plaintiff representing the broader class. This is a procedural milestone, not a final judgment. The lawsuit is in its early stages, ADMA has denied wrongdoing, and no court has yet ruled on the merits of the allegations. The company's rebuttal remains on the record, and Culper's short position introduces a structural conflict of interest that any jury will eventually weigh.

What the case does illuminate — regardless of its ultimate outcome — is the particular vulnerability of specialty biopharmaceutical companies with single-product revenue concentration and limited public visibility into their distribution arrangements. When 71 cents of every revenue dollar at ADMA traces back to a single drug sold through a distribution network whose counterparty relationships may not be fully disclosed, the information asymmetry between management and outside investors is profound. Analysts who praised the 51% ASCENIV growth figure did not have access to the distribution contracts, the payment terms, or the identity of the warehousing counterparties. They had what the company chose to put in its public filings. The lawsuit argues that what was in those filings was not the full picture — and a federal court will now have to decide whether the gap between what was disclosed and what was real constitutes fraud.